1. Home
  2. PRO vs NEO Comparison

PRO vs NEO Comparison

Compare PRO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROS Holdings Inc.

PRO

PROS Holdings Inc.

HOLD

Current Price

$23.25

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$11.92

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRO
NEO
Founded
1985
2001
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Precision Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2007
1999

Fundamental Metrics

Financial Performance
Metric
PRO
NEO
Price
$23.25
$11.92
Analyst Decision
Buy
Buy
Analyst Count
7
10
Target Price
$24.54
$12.56
AVG Volume (30 Days)
1.2M
1.8M
Earning Date
10-27-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$351,682,000.00
$709,162,000.00
Revenue This Year
$10.50
$10.90
Revenue Next Year
$10.86
$9.88
P/E Ratio
N/A
N/A
Revenue Growth
8.92
10.10
52 Week Low
$13.61
$4.72
52 Week High
$29.84
$19.12

Technical Indicators

Market Signals
Indicator
PRO
NEO
Relative Strength Index (RSI) 76.65 62.15
Support Level $23.06 $11.59
Resistance Level $23.20 $12.26
Average True Range (ATR) 0.05 0.48
MACD -0.04 -0.05
Stochastic Oscillator 95.24 72.49

Price Performance

Historical Comparison
PRO
NEO

About PRO PROS Holdings Inc.

Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: